182 related articles for article (PubMed ID: 25126956)
1. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.
Olsen J; Espersen ML; Jess P; Kirkeby LT; Troelsen JT
Surg Oncol; 2014 Sep; 23(3):167-76. PubMed ID: 25126956
[TBL] [Abstract][Full Text] [Related]
2. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
3. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer.
Olsen J; Eiholm S; Kirkeby LT; Espersen ML; Jess P; Gögenür I; Olsen J; Troelsen JT
Exp Mol Pathol; 2016 Feb; 100(1):59-66. PubMed ID: 26551082
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of CDX2 in colorectal cancers.
Choi BJ; Kim CJ; Cho YG; Song JH; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY; Park WS
APMIS; 2006 Jan; 114(1):50-4. PubMed ID: 16499661
[TBL] [Abstract][Full Text] [Related]
5. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
[TBL] [Abstract][Full Text] [Related]
6. CDX2 is an amplified lineage-survival oncogene in colorectal cancer.
Salari K; Spulak ME; Cuff J; Forster AD; Giacomini CP; Huang S; Ko ME; Lin AY; van de Rijn M; Pollack JR
Proc Natl Acad Sci U S A; 2012 Nov; 109(46):E3196-205. PubMed ID: 23112155
[TBL] [Abstract][Full Text] [Related]
7. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation downregulates CDX2 expression in colorectal carcinomas.
Kawai H; Tomii K; Toyooka S; Yano M; Murakami M; Tsukuda K; Shimizu N
Oncol Rep; 2005 Mar; 13(3):547-51. PubMed ID: 15706431
[TBL] [Abstract][Full Text] [Related]
9. Involvement of CDX2 in the cross talk between TNF-α and Wnt signaling pathway in the colon cancer cell line Caco-2.
Coskun M; Olsen AK; Bzorek M; Holck S; Engel UH; Nielsen OH; Troelsen JT
Carcinogenesis; 2014 May; 35(5):1185-92. PubMed ID: 24501326
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
11. Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells.
Olsen AK; Coskun M; Bzorek M; Kristensen MH; Danielsen ET; Jørgensen S; Olsen J; Engel U; Holck S; Troelsen JT
Carcinogenesis; 2013 Jun; 34(6):1361-9. PubMed ID: 23393221
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
13. Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2.
Modica S; Morgano A; Salvatore L; Petruzzelli M; Vanier MT; Valanzano R; Esposito DL; Palasciano G; Duluc I; Freund JN; Mariani-Costantini R; Moschetta A
Gut; 2009 Sep; 58(9):1250-9. PubMed ID: 19221108
[TBL] [Abstract][Full Text] [Related]
14. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
Zheng J; Sun X; Wang W; Lu S
Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
[TBL] [Abstract][Full Text] [Related]
16. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
17. [Expression of Cdx2 protein in colorectal cancer].
Pack JH; Kim TD; Oh HA; Lee EJ; Kim JW; Jang BI; Kim TN; Jung MK; Bae YK
Korean J Gastroenterol; 2005 Sep; 46(3):204-10. PubMed ID: 16179840
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway.
Krueger F; Madeja Z; Hemberger M; McMahon M; Cook SJ; Gaunt SJ
Cell Signal; 2009 Dec; 21(12):1846-56. PubMed ID: 19686845
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of caudal type homeobox transcription factor 2 inhibits the growth of the MGC-803 human gastric cancer cell line in vivo.
Wei W; Li L; Wang X; Yan L; Cao W; Zhan Z; Zhang X; Yu H; Xie Y; Xiao Q
Mol Med Rep; 2015 Jul; 12(1):905-12. PubMed ID: 25738600
[TBL] [Abstract][Full Text] [Related]
20. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
